AURORA SPINE CORPORATION ANNOUNCES AMENDMENT TO LOAN FROM INSIDER




AURORA SPINE CORPORATION ANNOUNCES AMENDMENT TO LOAN FROM INSIDER

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

Carlsbad, California, March 04, 2026 (GLOBE NEWSWIRE) — Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG) (OTCQB: ASAPF) announced today this it has amended an existing loan (the “Loan”) in the principal amount of US$1,600,000 plus accrued and unpaid interest in the amount of US$1,249,500 from an insider of the Company. The Company has been using the Loan proceeds for general corporate purposes.

The Loan, evidenced by a promissory note (the “Note”) bears interest at 9% per annum. The Amendment reduces the interest rate to 4.5% per annum effective January 1, 2026.  If an Event of Default occurs and continues, the outstanding balance of the Note, including all accrued and unpaid interest, will bear interest at a rate of Twelve Percent (12%) per annum, or at the maximum rate of interest under applicable law. The Principal Amount together with interest thereon, was due on the Maturity Date of June 29, 2027.  The parties have agreed to extend the Maturity Date to July 11, 2029. The parties also agreed that upon a Change of Control of the Company, the Maturity Date will be accelerated, and the Note will be due and payable in full, upon written request from the Holder. The Company may prepay the outstanding principal amount and accrued and unpaid interest thereon, in whole or in part, at any time without penalty. The Company’s wholly owned subsidiary, Aurora Spine, Inc., continues its guarantee and security for the obligations of the Company under the Note.

The Loan constitutes a “related party transaction” within the meaning of Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions (“MI 61-101”) and the policies of the TSX Venture Exchange but is otherwise exempt from the formal valuation and minority approval requirements of MI 61-101. The Company was not in a position to file a material change report more than twenty-one days in advance of the completion of the Loan.

The Loan is subject to certain conditions including, but not limited to, the receipt of all necessary approvals.

Neither the TSX Venture Exchange, nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange), accepts responsibility for the adequacy or accuracy of this release.

About Aurora Spine

Aurora Spine Corporation (TSXV: ASG) (OTCQB: ASAPF) is an innovative designer and manufacturer of minimally invasive spinal implants and interventional pain management technologies. Headquartered in Carlsbad, California, the company’s mission is to improve spinal surgery outcomes through simplified, integrated, and cost-effective solutions that advance patient care worldwide.

Additional information can be accessed at www.aurora-spine.com or www.aurorapaincare.com.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This news release contains statements that constitute “forward-looking information” within the meaning of applicable Canadian securities laws and “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 (collectively, “forward-looking statements”). Forward-looking statements include, but are not limited to, statements regarding the manner and timing of repayment of the Loan.

Forward-looking statements are based on management’s current expectations and assumptions and are subject to known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied. Readers are cautioned not to place undue reliance on forward-looking statements. Aurora Spine undertakes no obligation to update or revise any forward-looking statement, except as required by applicable securities laws.

Company and Investor Contacts

Aurora Spine Corporation

Trent J. Northcutt
President and Chief Executive Officer
Phone: (760) 424-2004

Chad Clouse
Chief Financial Officer
Phone: (760) 424-2004

Investor Relations
Adam Lowensteiner
Lytham Partners
Phone: (646) 829-9702
Email: asapf@lythampartners.com                               

Actuate Therapeutics to Present at The Citizens Life Sciences Conference




Actuate Therapeutics to Present at The Citizens Life Sciences Conference

CHICAGO and FORT WORTH, Texas, March 04, 2026 (GLOBE NEWSWIRE) — Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today announced that Dan Schmitt, President & CEO of the Company, will present at the Citizens Life Sciences Conference in Miami Beach, FL on Tuesday, March 10, 2026, at 8:25 a.m. ET.

The webcast of Mr. Schmitt’s presentation will be available at:

https://event.summitcast.com/view/BuMiPNPtyHKimMF6k4AFMd/guest_book?session_id=PW9gAwrMfrWWSf34Hno6ah

The Actuate management team will be available for one-on-one meetings with registered conference attendees.

A live link to the presentation will be located under “Events” in the Investors section of the Company’s website at www.actuatetherapeutics.com. A replay of the webcast will be available on Actuate’s website for 30 days following the presentation.

About Actuate Therapeutics, Inc.

Actuate is a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers. Actuate’s lead investigational drug, elraglusib (a novel GSK-3β inhibitor), targets molecular pathways in cancer that are involved in promoting tumor growth and resistance to conventional cancer drugs such as chemotherapy through the inhibition of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) and DNA Damage Response (DDR). Elraglusib may also mediate anti-tumor immunity through the regulation of multiple immune checkpoints and immune cell function.

For additional information, please visit the Company’s website at www.actuatetherapeutics.com or follow us on LinkedIn, X, and Facebook.

Forward Looking Statements

This press release contains forward-looking statements about us, including our and other parties’ clinical trials and development plans, and our industry. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would,” or the negative of these terms or other comparable terminology are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. All statements, other than statements related to present facts or current conditions or of historical facts, contained in this press release are forward-looking statements. Accordingly, these statements involve estimates, assumptions, substantial risks and uncertainties which could cause actual results to differ materially from those expressed in them, including but not limited to that preliminary and unpublished data may be subject to change and further interpretation following the availability of more data or following a more comprehensive review of the data and should not be relied upon as a final analysis; clinical and preclinical drug development involves a lengthy and expensive process with uncertain timelines and outcomes, results of prior preclinical studies, early clinical trials and sub-group studies are not necessarily predictive of future results and may not correlate with improved responses, and elraglusib may not achieve positive clinical results or favorable preclinical results or receive regulatory approval on a timely basis, if at all; that we may not successfully enroll additional patients or establish or advance plans for further development, including through conversations with the FDA or EMA and the standards such bodies may impose for such development; that elraglusib could be associated with side effects, adverse events or other properties or safety risks, which could delay or preclude regulatory approval, cause us to suspend or discontinue clinical trials or result in other negative consequences; our reliance on third parties to conduct our non-clinical studies and our clinical trials; our reliance on third-party licensors and ability to preserve and protect our intellectual property rights; that we face significant competition from other biotechnology and pharmaceutical companies; our ability to fund development activities, including because our financial condition raises substantial doubt as to our ability to continue as a going concern and we require additional capital to finance our operations beyond the second quarter of fiscal year 2026, and a failure to obtain this necessary capital in the near term on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our development programs, commercialization efforts or other operations. In addition, any forward-looking statements are qualified in their entirety by reference to the factors discussed under the heading “Item 1A. Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 13, 2025, and our Quarterly Reports on Form 10-Q, and other filings with the SEC. Because the risk factors referred to above could cause actual results or outcomes to differ materially from those expressed in any forward-looking statements made by us or on our behalf, you should not place undue reliance on any forward-looking statements. Further, any forward-looking statement speaks only as of the date on which it is made. New factors emerge from time to time, and it is not possible for us to predict which factors will arise. In addition, we cannot assess the impact of each factor on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Unless legally required, we do not undertake any obligation to release publicly any revisions to such forward-looking statements to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events.

Investor Contact
Mike Moyer
Managing Director
LifeSci Advisors, LLC
mmoyer@lifesciadvisors.com

Media Contact
Ignacio Guerrero-Ros, Ph.D.
Russo Partners, LLC
Ignacio.guerrero-ros@russopartnersllc.com
(858) 717-2310

Teladoc Health Announces Employee Inducement Award under NYSE Rule 303A.08




Teladoc Health Announces Employee Inducement Award under NYSE Rule 303A.08

NEW YORK, March 04, 2026 (GLOBE NEWSWIRE) — Teladoc Health, Inc. (NYSE:TDOC), the global leader in virtual care, today announced that it issued an inducement award to a new employee.

Effective March 1, 2026, in connection with commencing employment as Chief Growth Officer, U.S. Group Health, Daniel Conroy was granted an award of restricted stock units covering 57,034 shares of Teladoc Health’s common stock, par value $0.001 per share (“Common Stock”), and an award of performance stock units covering a target of 57,034 shares of Common Stock (for which up to 114,068 shares may be earned). The restricted stock units vest, based on continued service to Teladoc Health, as to one-third of the underlying shares on the first anniversary of the grant date, with the remainder vesting quarterly over two years thereafter. The performance stock units provide a target number of shares of Common Stock that would be earned over three years based on various financial metrics. The award was approved by the Compensation Committee of the Board of Directors of Teladoc Health and was granted under the Teladoc Health, Inc. 2023 Employment Inducement Incentive Award Plan as an employment inducement award pursuant to New York Stock Exchange Rule 303A.08.

About Teladoc Health

Teladoc Health (NYSE: TDOC) is the global leader in virtual care. The company is delivering and orchestrating care across patients, care providers, platforms, and partners — transforming virtual care into a catalyst for how better health happens. Through our relationships with health plans, employers, providers, health systems and consumers, we are enabling more access, driving better outcomes, extending provider capacity and lowering costs. Learn more at teladochealth.com.

Media:
Lou Serio
pr@teladochealth.com

Lifecore Biomedical Signs New Agreement with Indomo to Support Innovative Drug/Device Combination Acne Treatment




Lifecore Biomedical Signs New Agreement with Indomo to Support Innovative Drug/Device Combination Acne Treatment

Indomo Developing Fast-Acting, At-Home Treatment for Inflammatory Acne Lesions to be Administered with the ClearPen^™, its Proprietary Intradermal Self-Injection Device

Lifecore to Manufacture Drug Batches in Preparation for Planned Clinical Trials

CHASKA, Minn. and BOSTON, Mass., March 04, 2026 (GLOBE NEWSWIRE) — Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), and Indomo, a clinical-stage company dedicated to expanding access to quality healthcare via innovative device-enabled therapeutics, today announced that the companies have entered into a new development services agreement through which Lifecore will provide Indomo with a range of CDMO services to support the continued development of its corticosteroid drug candidate, DT-001. Indomo is developing DT-001 to be combined with its investigational intradermal self-injection device, the ClearPen^™, as a treatment for inflammatory acne lesions.

This represents the second agreement signed by the companies, with Lifecore having previously been selected to provide formulation and process optimization activities in support of the DT-001 program. Under the terms of the latest agreement, Lifecore will be responsible for producing and supplying engineering and clinical batches of DT-001 to Indomo for planned studies designed to prepare the product for anticipated advancement into Phase 2 clinical trials in 2026.

“We are thrilled to continue to grow our relationship with Indomo and support a customer that possesses such high-quality leadership and ambitious plans for innovation. This work with Indomo highlights the success of our continued efforts to expand beyond our traditional focus in ophthalmic therapies, while also enhancing our leadership in rapidly growing autoinjector technologies,” said Paul Josephs, president and chief executive officer of Lifecore. “We are excited to get to work on producing engineering and clinical batches for Indomo and supporting the company’s plans to move into Phase 2 studies.”

Built by a team with deep expertise in medical devices, consumer health, and skincare, Indomo’s investigational ClearPen system pairs a proprietary self-injection device and microneedle with a modernized formulation of triamcinolone acetonide to enable consistent dosing for at-home administration.

Intralesional injections of triamcinolone acetonide, a corticosteroid backed by more than 50 years of clinical use and a strong safety profile, are recommended as one of the first-line treatments for acne by the American Academy of Dermatology. Acne is the most common skin condition in the U.S., affecting 50 million Americans annually, yet only one million people are regularly receiving corticosteroid injections to treat their inflammatory lesions. The root cause of this issue is accessibility. With only 12,000 dermatologists in the U.S., there is only one dermatologist for every 28,000 Americans. Indomo aims to improve access by pursuing an at-home approach intended to empower patients with timely access to care.

“As we progress toward Phase 2 studies, it was critical for Indomo to partner with a CDMO that combines technical excellence with a forward-looking approach to innovation. Lifecore’s expanding leadership in injectable therapeutics and their commitment to speed and high-quality execution position them as a key partner in advancing our therapeutic pipeline. We are excited to deepen this collaboration as we move into the next phase of development,” said Rick Bente, chief executive officer of Indomo.

About Lifecore Biomedical
Lifecore Biomedical, Inc. (Nasdaq: LFCR) is a fully integrated contract development and manufacturing organization (CDMO) that offers highly differentiated capabilities in the development, fill and finish of sterile injectable pharmaceutical products in syringes, vials, and cartridges, including complex formulations. As a leading manufacturer of premium, injectable-grade hyaluronic acid, Lifecore brings more than 40 years of expertise as a partner for global and emerging biopharmaceutical and biotechnology companies across multiple therapeutic categories to bring their innovations to market. For more information about the company, visit Lifecore’s website at www.lifecore.com.

About Indomo
Indomo is reimagining clinical dermatology with trusted science and precision technology, bringing medical-grade care into the home. A clinical-stage therapeutics company, Indomo pairs proven medicines with novel delivery systems to create fast-acting, self-administered treatments for inflammatory skin conditions. Its debut product, the ClearPen, will combine an established, trusted therapeutic with a novel microneedle device for at-home acne treatment. Indomo is backed by leading investors including Atomic, Foresite Capital, and Polaris Partners. Founded by leaders from Hims & Hers, Medtronic, and Starface, Indomo brings together deep expertise in telehealth, medical devices, and consumer skincare. To learn more about Indomo and their Phase 2 clinical trials, head here.

Disclaimer: The Indomo ClearPen has not yet been approved or cleared by the U.S. Food and Drug Administration and is considered investigational; preparations are underway for Phase 2 clinical trials.

Important Cautions Regarding Forward-Looking Statements

This press release contains forward-looking statements regarding future events and Lifecore’s future results that are subject to the safe harbor created under the Private Securities Litigation Reform Act of 1995 and other safe harbors under the Securities Act of 1933 and the Securities Exchange Act of 1934. Words such as “anticipate”, “estimate”, “expect”, “project”, “plan”, “intend”, “believe”, “may”, “might”, “will”, “should”, “can have”, “likely” and similar expressions are used to identify forward-looking statements. In addition, all statements regarding Lifecore’s expansion of Lifecore’s CDMO business, broadening of Lifecore’s commercial customer base, the anticipated advancement of Indomo’s DT-001 program into Phase 2 clinical trials in 2026, our efforts to expand beyond Lifecore’s traditional focus in ophthalmic therapies, enhancing Lifecore’s leadership in rapidly growing autoinjector technologies, Lifecore’s forward-looking approach to innovation, Lifecore’s expanding leadership in injectable therapeutics, and Lifecore’s commitment to speed and high-quality execution are forward-looking statements. All forward-looking statements involve certain risks and uncertainties that could cause actual results to differ materially, including such factors among others, the timing and amount of future expenses, revenue, net income (loss), Adjusted EBITDA, cash flow and capital requirements, and timing and availability of and the need for additional financing; Lifecore’s ability to maintain or expand Lifecore’s relationships with Lifecore’s current customers, including the impact of changes in consumer demand for the products Lifecore manufactures for Lifecore’s customers; Lifecore’s ability to grow and diversify Lifecore’s business with new customers, including the potential loss of development customers or delays in our development customers’ programs if they do not receive required funding or regulatory approvals, or for other reasons; Lifecore’s ability to comply with covenants under Lifecore’s credit agreements and to pay required interest and principal payments when due; Lifecore’s ability to fund any redemptions of shares of its outstanding Series A Convertible Preferred Stock if requested by holders in accordance with their terms; Lifecore’s ability to raise additional capital for ongoing needs, including through equity financing, debt financing, collaborations, strategic alliances or licensing arrangements; the impact of macroeconomic events or circumstances on Lifecore’s operations and financial performance, including inflation, tariffs, interest rates, social unrest and global instability; the performance of Lifecore’s third-party suppliers; pharmaceutical industry market forces that may impact Lifecore’s customers’ success and continued demand for the products Lifecore produces for those customers; Lifecore’s ability to recruit or retain key scientific, technical, business development, and management personnel and Lifecore’s executive officers; Lifecore’s ability to comply with stringent U.S. and foreign government regulation in the manufacture of pharmaceutical products, including current Good Manufacturing Practice, or cGMP; the outcome and cost of existing and any new litigation or regulatory proceedings; and other risk factors set forth from time to time in the company’s filings with the Securities and Exchange Commission (“SEC”), including, but not limited to, the Annual Report on Form 10-K for the year ended May 25, 2025 (the “2025 10-K”). For additional information about factors that could cause actual results to differ materially from those described in the forward-looking statements, please refer to Lifecore’s filings with the SEC, including the risk factors contained in the 2025 10-K. Forward-looking statements represent management’s current expectations as of the date hereof and are inherently uncertain. Except as required by law, Lifecore does not undertake any obligation to update forward-looking statements made by us to reflect subsequent events or circumstances.

Lifecore Biomedical, Inc. Contact Information:

Vida Strategic Partners
Stephanie Diaz (Investors & Media)
415-675-7401
sdiaz@vidasp.com

Ryan D. Lake (CFO)
Lifecore Biomedical
952-368-6244
ryan.lake@lifecore.com

FemPulse Pivotal Study Selected For Presentation at the American Urological Association Annual Conference




FemPulse Pivotal Study Selected For Presentation at the American Urological Association Annual Conference

SAN FRANCISCO, March 04, 2026 (GLOBE NEWSWIRE) — FemPulse™, a bioelectronic medical technology company with first application overactive bladder (OAB), announced today that the Company’s pivotal clinical study was selected for presentation on the opening day of the American Urological Association (AUA) annual conference in Washington, DC Friday, May 15, 2026.

AUA’s conference is the largest annual meeting of urologists worldwide, and the Clinical Trials in Progress program is, “designed to increase awareness of important clinical trials …that are expected to substantially influence practice.” FemPulse’s presentation follows the Company’s recent February 27 presentation of positive results of two usability studies at the Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction (SUFU).

OAB is a chronic, progressive condition impacting quality-of-life for up to 40% of women. The most recent AUA/SUFU OAB Guidelines recommend clinicians, “offer select non-invasive therapies to all patients with OAB,” and research confirms women prefer a wearable device to any other treatment. Medication is often ineffective with potentially intolerable side-effects while neuromodulation is efficacious but has historically required a surgery.

FemPulse has developed a wearable vaginal wireless neuromodulation ring that women can insert, wear continuously, and remove themselves. The FemPulse Ring is unique in being self-retained in the upper vagina with eight programmable surface electrodes directly targeting the nerves that control communication between the bladder and the spinal cord. Four previous IRB NSR studies totaling 51 subjects have met all safety endpoints and provided signals of efficacy.

Dr. Suzette E. Sutherland, Principal Investigator (PI), will present FemPulse’s ongoing EVANESCE-II pivotal study, a prospective, multi-center randomized controlled trial (RCT) with up to 151 female OAB subjects randomized 2:1 to FemPulse or standard-of-care OAB medication. “I am excited to again serve as PI for this pivotal trial after seeing the previous positive results. FDA’s rare approval of a device vs. drug trial underscores the great need for a simple, non-invasive device option for the enormous OAB patient population,” said Dr. Sutherland.

Dr. Roger Dmochowski is serving as the study’s Independent Safety Monitor (ISM). “I agreed to serve as the safety monitor for FemPulse’s pivotal trial based on the strong safety profile demonstrated previously. After two decades involvement with OAB reimbursement, I am also acutely aware of the potential benefits to patients, providers, and payors of this unique non-surgical neuromodulation option,” said Dr. Dmochowski.

About FemPulse
FemPulse Corporation is a bioelectronic medicine company developing a novel wearable platform for the personalized treatment of medical conditions in women. FemPulse’s vaginally-inserted, wearable neuromodulation Ring is intended to provide mild electrical nerve stimulation as a first-line alternative to pharmaceutical medications. The initial application is to treat the one in six women worldwide suffering from overactive bladder (OAB). The device is investigational and not approved for commercial sale in any jurisdiction. For more information, visit www.fempulse.com.

Investor Contact:

Peter Fredericks, Chairman
FemPulse Corporation
pfredericks@fempulse.com

Can-Fite Announces Exercise of Warrants for Approximately $4.0 Million in Gross Proceeds




Can-Fite Announces Exercise of Warrants for Approximately $4.0 Million in Gross Proceeds

RAMAT GAN, Israel, March 04, 2026 (GLOBE NEWSWIRE) — Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF) (“Can-Fite” or the “Company”), a biotechnology company advancing a pipeline of proprietary small-molecule drugs targeting oncological and inflammatory diseases, today announced the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 795,869 American Depositary Shares (ADSs), having an exercise price of $9.34 per ADS, issued by Can-Fite in July 2025, at a reduced exercise price of $5.00 per ADS. The ADSs representing ordinary shares issuable upon exercise of the warrants are registered pursuant to an effective registration statement on Form F-1 (File No. 333-288890). The closing of the offering is expected to occur on or about March 5, 2026, subject to satisfaction of customary closing conditions.

H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.

In consideration for the immediate exercise of the warrants for cash, Can-Fite will issue new unregistered warrants to purchase up to 1,591,738 ADSs. The new warrants will have an exercise price of $5.00 per ADS, will be immediately exercisable until the twenty-four month anniversary of the effective date of the Resale Registration Statement.

The gross proceeds to Can-Fite from the exercise of the warrants are expected to be approximately $4.0 million, prior to deducting placement agent fees and offering expenses. The Company intends to use the net proceeds for funding research and development and clinical trials and for other working capital and general corporate purposes.

The new warrants described above were offered in a private placement pursuant to an applicable exemption from the registration requirements of the Securities Act of 1933, as amended (the “1933 Act”), and, along with the ADSs issuable upon exercise, have not been registered under the 1933 Act, and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission (“SEC”) or an applicable exemption from such registration requirements. Can-Fite has agreed to file a registration statement with the SEC covering the resale of the shares of ADSs issuable upon exercise of the new warrants (the “Resale Registration Statement”).

This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities in this offering, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Can-Fite BioPharma Ltd.

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF) is an advanced clinical stage drug development Company with a platform technology that is designed to address multi-billion-dollar markets in the treatment of cancer, liver, and inflammatory disease. The Company’s lead drug candidate, Piclidenoson reported topline results in a Phase III trial for psoriasis and commenced a pivotal Phase III trial. Can-Fite’s liver drug, Namodenoson, is being evaluated in a Phase III trial for hepatocellular carcinoma (HCC), a Phase IIb trial for the treatment of MASH, and in a Phase IIa study in pancreatic cancer. Namodenoson has been granted Orphan Drug Designation in the U.S. and Europe and Fast Track Designation as a second line treatment for HCC by the U.S. Food and Drug Administration. Namodenoson has also shown proof of concept to potentially treat other cancers including colon, prostate, and melanoma. CF602, the Company’s third drug candidate, has shown efficacy in the treatment of erectile dysfunction. These drugs have an excellent safety profile with experience in over 1,600 patients in clinical studies to date. For more information please visit: https://www.canfite.com/.  

Forward-Looking Statements

This press release may contain forward-looking statements, about Can-Fite’s expectations, beliefs or intentions regarding, among other things, its product development efforts, business, financial condition, results of operations, strategies or prospects. All statements in this communication, other than those relating to historical facts, are “forward looking statements”. Forward-looking statements can be identified by the use of forward-looking words such as “believe,” “expect,” “intend,” “plan,” “may,” “should” or “anticipate” or their negatives or other variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical or current matters. For example, the Company is using forward-looking statements when it discusses the completion of the offering, the satisfaction of customary closing conditions related to the offering and the intended use of proceeds therefrom. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to known and unknown risks, uncertainties and other factors that may cause Can-Fite’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause actual results, performance or achievements to differ materially from those anticipated in these forward-looking statements include, among other things, our market and other conditions, history of losses and needs for additional capital to fund our operations and our inability to obtain additional capital on acceptable terms, or at all; uncertainties of cash flows and inability to meet working capital needs; the initiation, timing, progress and results of our preclinical studies, clinical trials and other product candidate development efforts; our ability to advance our product candidates into clinical trials or to successfully complete our preclinical studies or clinical trials; our receipt of regulatory approvals for our product candidates, and the timing of other regulatory filings and approvals; the clinical development, commercialization and market acceptance of our product candidates; our ability to establish and maintain strategic partnerships and other corporate collaborations; the implementation of our business model and strategic plans for our business and product candidates; the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and our ability to operate our business without infringing the intellectual property rights of others; competitive companies, technologies and our industry; risks related to not satisfying the continued listing requirements of NYSE American; and statements as to the impact of the political and security situation in Israel on our business. More information on these risks, uncertainties and other factors is included from time to time in the “Risk Factors” section of Can-Fite’s Annual Report on Form 20-F filed with the SEC on April 14, 2025 and other public reports filed with the SEC and in its periodic filings with the TASE. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Can-Fite undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws.

Contact

Can-Fite BioPharma
Motti Farbstein
info@canfite.com 
+972-3-9241114

Baylor Genetics to Highlight New Data and Product Innovations at 2026 ACMG Annual Clinical Genetics Meeting




Baylor Genetics to Highlight New Data and Product Innovations at 2026 ACMG Annual Clinical Genetics Meeting

Company’s exhibit theater presentation will highlight multiomic and multimodal innovations in rare disease diagnostics

HOUSTON, March 04, 2026 (GLOBE NEWSWIRE) — Baylor Genetics, a leading diagnostic genomics partner offering a full spectrum of comprehensive genetic tests and diagnostic services, will showcase its latest scientific studies and product innovations at the 2026 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting on March 10-14 in Baltimore, MD. The company will highlight its innovative portfolio at booth #1017 and share a series of presentations and poster sessions throughout the meeting.

“The studies we’re sharing at ACMG reinforce the power of genome sequencing in providing meaningful, actionable answers to complex genetic disorders – from families navigating rare pediatric diseases to patients finally receiving the long-awaited answers needed to support their care plans,” said Christine Eng, MD, Chief Medical Officer and Chief Quality Officer at Baylor Genetics. “Scientific advancements play a fundamental role in transforming the future of care, and we’re proud to highlight how our latest findings and product innovations are enabling clinical teams to deliver more timely answers and informed care plans for patients and their families.”

Exhibit Theater Presentation

A presentation titled “Putting Patients First: Innovative Multiomic and Multimodal Solutions for Rare Disease Diagnostics” will feature Christine Eng, MD and Chris Sands, Chief Growth Officer at Baylor Genetics. The session takes place in Exhibit Theater 2 on Friday, March 13 from 12:30-1:00 p.m. EST.

Platform Presentation

A platform presentation titled “Diagnostic Yield of Rapid Genome Sequencing in Critically Ill Infants with Cardiac Indications,” will be presented by Lisa Salz, MS, CGC, Senior Medical Science Liaison at Baylor Genetics, on Friday, March 13 at 1:30 p.m. EST on Platform 8, Ballroom IV – Rapid WGS and Newborn Screening.

Poster Presentations

Thursday, March 12 from 10:30 – 11:30 a.m. EST

• Poster #P177: Prevalence of Incidental Findings in Pharmacogenomic Panel Testing
  • Presenting author: Lauren Marcath, PharmD

• Poster #P501: Demographic and Geographic Considerations in Pediatric Genome Sequencing: A Diagnostic Laboratory Review
  • Presenting author: Chad Moretz, ScD

• Poster #P561: Expanding the Genotypic Spectrum for ReNU Syndrome: A Clinical Laboratory Experience.
  • Presenting author: Robert Rigobello, MS, CGC 

• Poster #P581: The Utility of Genome Sequencing as a Diagnostic Tool for Children with Ataxia.
  • Presenting author: Morgan Driver, PhD, MS, CGC 

• Poster #P661: Uniparental Disomy Detection in a Clinical Trio Genome Sequencing Cohort.  
  • Presenting author: Bo Yuan, PhD 

Friday, March 13 from 10:30 – 11:30 a.m. EST

• Poster #P196: WDTC1 Haploinsufficiency is Associated with the Development of Neurodevelopmental Phenotypes and Seizures
  • Presenting author: Elyssa Smith, BS 

• Poster #P564: Genome and Exome Sequencing Reanalysis: Improvement to Diagnostic Yield and Classification of Variants Over Time.
  • Presenting author: Morgan Driver, PhD, MS, CGC 

• Poster #P676: Sex Chromosome Abnormalities Are a Major CMA and Chromosome Diagnostic Finding for Ambiguous Genitalia
  • Presenting author: Laleh Abbassi, PhD 

• Poster #P696: Genome Sequencing Diagnoses Atypical 7q11.23 Region Deletion in an Adult Patient.
  • Presenting author: Nichole Owen, PhD, FACMG 

• Poster #P710: Diagnostic Utility of Genome and Transcriptome Sequencing in Identifying PIGL Variants Associated with Atypical CHIME Syndrome.
  • Presenting author: Hongzheng Dai, PhD 

For more information about Baylor Genetics’ presence at ACMG, please visit: https://www.baylorgenetics.com/conferences/acmg-2026/. Updates will also be shared on the company’s LinkedIn channel throughout the meeting.

About Baylor Genetics
Baylor Genetics is a leading diagnostic genomics partner offering a full spectrum of comprehensive genetic tests and diagnostic services, from clinical-grade genomic sequencing to expert interpretation, including Whole Genome Sequencing, Whole Exome Sequencing, and focused panels. Baylor Genetics combines rapid and comprehensive precision diagnostics options with the support of genetic counselors to help clinicians avoid a lengthy diagnostic odyssey for their patients, guide medical management, and ensure no patient with a genetic disorder gets left behind. Baylor Genetics’ testing menu covers family planning, pregnancy, neonatal and pediatric testing, oncology, pharmacogenomics and many other specialized testing options. Located in Houston’s Texas Medical Center, Baylor Genetics serves clients in 50 states.

PR Contact
SVM PR
baylorgenetics@svmpr.com
(401) 490-9700

Standard Process® Launches Canine Cognition Support to Help Aging Dogs Maintain Brain Health




Standard Process® Launches Canine Cognition Support to Help Aging Dogs Maintain Brain Health

New Veterinary Formulas™ supplement supports alertness and awareness with clinically researched ingredients

PALMYRA, Wis., March 04, 2026 (GLOBE NEWSWIRE) — Standard Process^®, a pioneer in whole food-based nutritional supplements, today announced the launch of Canine Cognition Support, a new addition to its Standard Process Veterinary Formulas™ line, developed exclusively for science-backed, veterinary-recommended care to support brain health, cognitive vitality, and healthy aging in dogs.

As dogs age, key changes in behavior — also referred to as DISHAA (Disorientation, altered social Interactions, altered Sleep-wake cycles, House soiling or loss of learned behaviors, Altered activity levels, and Anxiety) — can signal cognitive and behavioral changes. Canine Cognition Support provides veterinarians with a science-backed nutritional solution to encourage alertness, awareness, and normal behaviors in aging dogs.

Canine Cognition Support is a powdered supplement formulated with a comprehensive blend of clinically researched ingredients, including Ginkgo Biloba, B vitamins, beta-glucans from Lion’s Mane Mushroom extract, Panax Ginseng, and CoQ10. Unlike single-ingredient products on the market, the antioxidants, botanicals, and herbs in this formulation work synergistically to support multiple pathways involved in brain health, including circulation, neurotransmitter production, and cellular energy metabolism.

In addition, the product features Swiss chard and buckwheat grown on the Standard Process Certified Organic Farm, reinforcing the company’s commitment to deliver nutrient-dense whole food ingredients and full traceability from soil to scientific testing to supplement.

“While pet owners may not be familiar with the clinical signs associated with aging dogs, they often recognize when their dog is slowing down, or no longer seems like themselves,” said Katrina Verdeur, MS in Food Science, Pet Product Development Manager at Standard Process. “Whole food-based, targeted supplementation plays a meaningful role in supporting these canines through age-related cognitive changes. We developed Canine Cognition Support to serve as the comprehensive solution pet parents need to support cognitive health span, and quality of life, for our beloved senior dogs.”

Veterinary practices today demand solutions that align with both clinical standards and pet owners’ needs. Canine Cognition Support was developed with more than 50 years of combined clinical experience to provide vets with a differentiated offering grounded in science-backed transparency to provide the best possible care for aging pet patients. Standard Process’ innovative formulations, organic whole food farming practices, and family-owned ethos make the company the chosen partner for veterinarians across the nation.

Where To Find

• Pet Parents: To connect with a veterinarian recommending Standard Process, please visit https://www.standardprocess.com/where-to-buy
• Veterinary Professionals interested in recommending this product to patients, please visit https://www.standardprocess.com/apply

About Standard Process^®
Standard Process has been a leader and innovator in whole food-based supplements since 1929. Now entering our fourth generation of family leadership, we are committed to clinical science that changes lives. We’re advancing the whole food health advantage with our Nutrition Innovation Center in Kannapolis, North Carolina; protecting vital nutrients with our elevated manufacturing techniques at our Palmyra, Wisconsin headquarters; and cultivating nutrient-dense crops at our Certified Organic Farm. We currently offer more than 300 high-quality supplements that are designed to support optimal wellness for the entire family — pets included. For more information about Standard Process and to find a health care professional who recommends Standard Process products, visit standardprocess.com.

Standard Process Contacts:
Tim Shaw, Senior Brand Manager
tshaw@standardprocess.com

Rebecca Dombrowski, Associate Brand Manager
rdombrowski@standardprocess.com

Media Contact:
Laura Bastardi, MWW Health
Standardprocess@mww.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/f7fe9131-b62e-4d8b-b044-9ab5523ad188

AIM ImmunoTech Announces Expiration and Preliminary Results of its Rights Offering for Aggregate Gross Proceeds of $1.8 Million




AIM ImmunoTech Announces Expiration and Preliminary Results of its Rights Offering for Aggregate Gross Proceeds of $1.8 Million

OCALA, Fla., March 04, 2026 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. (NYSE American: AIM) – AIM ImmunoTech Inc. (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of its lead product, Ampligen® (rintatolimod), for the treatment of late-stage pancreatic cancer – a lethal and unmet global health problem – today announced the preliminary results of its previously announced rights offering (the “Rights Offering”) which expired at 5:00 p.m., Eastern Time, on March 3, 2026. The Company estimates that the Rights Offering will result in total subscriptions of approximately $1.8 million. The results of the Rights Offering are preliminary and subject to change pending finalization and verification by the Company and its subscription agent, Broadridge Corporate Issuer Solutions, LLC.

Each right entitled the holder to purchase one unit (“Unit”), at a subscription price of $1,000 per Unit, consisting of one share of the Company’s Series G Convertible Preferred Stock (the “Preferred Stock”), and 2,000 Class G Common Stock Purchase Warrants to purchase the Company’s Common Stock (the “Warrants”).

The Company anticipates the closing of the Rights Offering will occur on or about March 6, 2026, subject to satisfaction or waiver of all conditions to closing. Upon the closing, the subscription agent will distribute, by way of direct registration in book-entry form or through the facilities of DTC, as applicable, shares of the Preferred Stock and Warrants to holders of rights who have validly exercised their rights and paid the subscription price in full. No physical stock or warrant certificates will be issued to such holders.

Maxim Group LLC acted as dealer-manager for the Rights Offering. Questions about the Rights Offering or requests for copies of the final prospectus may be directed to Maxim Group LLC at 300 Park Avenue, New York, NY 10022, Attention: Syndicate Department, or via email at syndicate@maximgrp.com or telephone at (212) 895-3745.

The Company’s registration statement on Form S-1 (Registration No. 333-292085) was declared effective by the Securities and Exchange Commission (“SEC”) on February 10, 2026. The prospectus relating to and describing the terms of the Rights Offering has been filed with the SEC as a part of the registration statement and is available on the SEC’s website at http://www.sec.gov.

This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About AIM ImmunoTech

AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of its lead product, Ampligen® (rintatolimod), for the treatment of late-stage pancreatic cancer, a lethal and unmet global health problem. Ampligen is a dsRNA and highly selective TLR3 agonist immuno-modulator that has shown broad-spectrum activity in clinical trials.

Forward Looking Statements

Some of the statements included in this press release may be forward-looking statements that involve a number of risks and uncertainties. Among other things, for those statements, the Company claims the protection of safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements set forth in the press release speak only as of the date of the press release. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. The Company is in various stages of seeking to determine whether Ampligen® will be effective in the treatment of multiple types of viral diseases, cancers, and immune-deficiency disorders and disclosures in the Company’s reports filed with the SEC on its website and in its press releases set forth its current and anticipated future activities. These activities are subject to change for a number of reasons. Significant additional testing and trials will be required to determine whether Ampligen® will be effective in the treatment of these conditions. Results obtained in animal models do not necessarily predict results in humans. Human clinical trials will be necessary to prove whether or not Ampligen® will be efficacious in humans. No assurance can be given as to whether current or planned clinical trials will be successful or yield favorable data and the trials are subject to many factors including lack of regulatory approval(s), lack of study drug, or a change in priorities at the institutions sponsoring other trials. Even if these clinical trials are initiated, the Company cannot assure that the clinical studies will be successful or yield any useful data or require additional funding. Among the studies are clinical trials that provide only preliminary data with a small number of subjects, and no assurance can be given that the findings in these studies will prove true or that the study or studies will yield favorable results. No assurance can be given that future studies will not result in findings that are different from those reported in the studies referenced in the Company’s reports filed with the SEC, on the Company’s website and in its press releases. Operating in foreign countries carries with it a number of risks, including potential difficulties in enforcing intellectual property rights. The Company cannot assure that its potential foreign operations will not be adversely affected by these risks.

Please review the “Risk Factors” section in the Company’s latest annual report on Form 10-K and subsequent quarterly reports on Form 10-Q and the registration statement. Its filings are available at www.aimimmuno.com. The information found on the Company’s website is not incorporated by reference herein and is included for reference purposes only.

CONTACT: IR Contact:

JTC Team, LLC

Jenene Thomas

908.824.0775

AIM@jtcir.com